New hope for rare blood cancer: phase 3 trial of XNW5004 launches
NCT ID NCT06776952
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This Phase 3 trial tests whether the experimental drug XNW5004 can help people with relapsed or refractory peripheral T-cell lymphoma, a rare and aggressive blood cancer. About 120 participants will receive either XNW5004 or the existing drug chidamide. The main goal is to see if XNW5004 delays cancer progression better than chidamide.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
XNW5004
What this could lead to
If it works, this could provide a new treatment option for people with relapsed or refractory peripheral T-cell lymphoma, potentially slowing disease progression.
What could go wrong
This is an early-stage Phase 3 trial with only 120 participants, so results may not apply to everyone. The drug may not be more effective than existing treatments and could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY PERIPHERAL T-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Friendship Hospital,Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••